Spotlight
Obituaries
Classifieds
Families First
VCAs Best of Guide
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Weather
25 NC counties are under alert, including Durham, Orange, and Person counties.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
79.29
+1.17 (+1.50%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
Today 3:22 EDT
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
Via
Benzinga
Topics
Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
July 31, 2025
Via
Stocktwits
Topics
Government
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
July 31, 2025
These stocks have all surged more than 1,000% since August 2020.
Via
The Motley Fool
Topics
Artificial Intelligence
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
July 30, 2025
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.
Via
Benzinga
Topics
Earnings
Earnings Scheduled For July 29, 2025
July 29, 2025
Via
Benzinga
Merck & Co's Earnings Outlook
July 28, 2025
Via
Benzinga
P/E Ratio Insights for Merck & Co
July 24, 2025
Via
Benzinga
Why Merck Stock Slipped Today
July 29, 2025
A change in full-year guidance by management wasn't particularly welcome.
Via
The Motley Fool
Is Merck & Co Gaining or Losing Market Support?
July 29, 2025
Via
Benzinga
Why Merck (MRK) Shares Are Sliding Today
July 29, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a...
Via
StockStory
Topics
Artificial Intelligence
Workforce
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
July 29, 2025
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.
Via
Benzinga
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
July 21, 2025
Via
Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
July 21, 2025
Via
Stocktwits
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
July 29, 2025
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
Via
Benzinga
These S&P500 stocks are gapping in today's session
July 29, 2025
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.
Via
Chartmill
Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan
July 29, 2025
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.
Via
Stocktwits
Topics
World Trade
Which S&P500 stocks are moving before the opening bell on Tuesday?
July 29, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via
Chartmill
Merck Posts Q2 EPS Beat Revenue Slips
July 29, 2025
Via
The Motley Fool
Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations
July 29, 2025
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was...
Via
StockStory
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
July 28, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via
The Motley Fool
Topics
Lawsuit
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact
July 28, 2025
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
Via
Benzinga
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
July 28, 2025
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.
Via
Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
July 28, 2025
These big pharma stocks arguably aren't receiving the respect they deserve.
Via
The Motley Fool
Topics
Intellectual Property
What To Expect From Merck’s (MRK) Q2 Earnings
July 27, 2025
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
July 26, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via
Benzinga
Topics
Artificial Intelligence
ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
July 25, 2025
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via
Benzinga
Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential
July 25, 2025
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.
Via
Chartmill
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
July 23, 2025
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via
Investor's Business Daily
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
July 22, 2025
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.
Via
Investor's Business Daily
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
July 22, 2025
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.